CA2260048A1 - Improved tissue injectable composition and method of use - Google Patents
Improved tissue injectable composition and method of use Download PDFInfo
- Publication number
- CA2260048A1 CA2260048A1 CA002260048A CA2260048A CA2260048A1 CA 2260048 A1 CA2260048 A1 CA 2260048A1 CA 002260048 A CA002260048 A CA 002260048A CA 2260048 A CA2260048 A CA 2260048A CA 2260048 A1 CA2260048 A1 CA 2260048A1
- Authority
- CA
- Canada
- Prior art keywords
- particles
- microns
- composition
- carbon
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0059—Cosmetic or alloplastic implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/08—Carbon ; Graphite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/10—Ceramics or glasses
- A61L27/105—Ceramics or glasses containing Al2O3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/303—Carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0004—Closure means for urethra or rectum, i.e. anti-incontinence devices or support slings against pelvic prolapse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/00574—Coating or prosthesis-covering structure made of carbon, e.g. of pyrocarbon
Abstract
An improved biocompatible composition consisting of physiologically stable beads or particles carried in a lubricative suspension, solution, other fluid or gel. The composition is intended to be delivered into the body through a small-bored needle, cannula, or other catheter into a tissue site for the purpose of augmenting the tissue. In particular, the composition is useful for augmenting tissue in the area of the cardiac orifice of the stomach to reduce gastric reflux, in the area of the internal or external sphincter of the anal canal to reduce fecal incontinence or in the area of urethral tissue for the purpose of treating urinary incontinence.
Description
W O 98101088 PCT~US97/10473 PnGVhV TISSUE INJ~CTPRT~ COMPOSITION }iND METHOD OF USE
Background of the Invention This invention relates to an injectable composition of physiologically compatible and appropriately sized particles carried in a lubricative, biologically compatible fluid or gel. The composition is formulated to be delivered into the body to a tissue site through a small-bore instrument to strengthen, bulk-up and otherwise augment the tissue site and surrounding area.
The percutaneous injection of substances into tissues to augment, support, or reconfigure anatomic structure has been the subject of significant research and product development and is well known in the art. See, for example, U.S. Patent Nos. 4,803,075 and 5,204,382 to Wallace et al., and U.S. Patent No. 5,258,028 to Ersek et al. Procedures have been described in the medical literature for correction of dermatological, otolaryngological problems and for treatment of urological di60rders, e.g., Smith et al., "Evaluation of Polydimethylsiloxane as an Alternative in the Endoscopic Treatment of Vesicoureteral Reflux", J. Urol., 152: 1221-1224, 1994, and Walker et al., "Injectable Bioglass as a P o t e n t i a l S u b s t i t ut e f o r I n j e c t a b l e Polytetrafluoroethylene", J. Urol., 148:645-7 (1992) and the references cited therein.
Urinary incontinence and vesicourethral reflux are urological disorders that have responded to treatments with augumentive materials. Incontinence occurs when the resistance to urine flow has decreased to the point where the resistance can no longer resist the intra-abdominal pressure. Nearly all procedures developed to restore continence are based on restoring the lost resistance to urine outflow. U.S. Patent Nos. 5,007,940; 5,158,573; and 5,116,387 to Berg disclose biocompatible compositions comprising discrete, polymeric and silicone rubber bodies injectable into urethral tissue for the purpose of treatment of urinary incontinence by tissue bulking.
Further, U.S. Patent No. 5,451,406 to Lawin, the inventor of -the present composition, discloses biocompatible W O98101088 PCT~US97/10473 compositions comprising carbon coated substrate particles injectable into a tissue, such as the tissues of and that overlay the urethra and b~ r nec~, for the purpose of treatment of urinary incontinence by tissue bulking.
The most serious adverse effects that may occur from therapies of this type relate to the migration of the solid materials from the original site of placement into repository sites in various body organs and the chronic inflammatory response of tissue to particles that are too small. These adverse effects are well documented in the urologic literature, specifically in Malizia, A.A., et al., "Migration and Granulomatous Reaction After Periurethral Injection of Polytef (Teflon)", JAMA 251:3277-3281 ~1984) and Claes, H., Stroobants, D. et al., "Pulmonary Migration Following Periurethral Polytetrafluoroethylene In~ection For Urinary Incontinence", J. Urol., 142:821-822 (1989).
An important factor in assuring the absence of migration is the A~mi ni stration of properly sized particles. If the particle is too small, it can be engulfed by the body's white cells (phagocytes) and carried to distant organs or be carried away in the microvasculature and travel until it reaches a site of greater constriction. Target organs for deposition include the lungs, liver, spleen, brain, kidney, and lymph nodes.
The use of small diameter particulate spheres, in the range of 1-20 microns, and small elongate fibrils having a diameter in the range 1-20 microns, formed of materials such a~ cross linked collagen or synthetic polymers suspen~A in an aqueous medium having biocompatible lubricant has been disclosed in Wallace et al., U.S. Patent No. 4,803,075. While these materials showed positive, short term augmentation results, this result was short lived as the material had a te~ncy to migrate and/or be absorbed by the host tissue.
Teflon paste was used early to treat stress urinary incontinence. Politano, V.A., Small, M.P., Harper, J.M., Lynne, C.M., "Periurethral Teflon In~ection for Urinary W O 98/01088 PCT~US97/10473 Incontinence", J.Urol., 111:180-183 (1974). The Teflon paste consisted of polytetrafluoroethylene particles in a size range of 1 to 100 microns. More than ninety percent of the particles were in the range of 1 to 40 microns.
Malizia, A.A. Reiman, H.M., Myers, R.P., et al., "Migration and Granulomatous Reaction After Periurethral Injection of Polytef (Teflon)", JAMA, 251:24:3277-3281 (1984). This product demonstrated foreign body granuloma formation at the injection site and local migration. Boedts, D., Roels, H., Kluyskens, P., "Laryngeal Tissue Responses to Teflon", Arch Otolaryngol, 86:562-567 (1967).
In a 1980's study, TEFLON particles were injected periurethrally into monkeys and dogs, approximating the technique used to treat humans. Malizia, A.A. Reiman, H.M., Myers, R.P., et al., "Migration and Granulomatous Reaction After Periurethral Injection of Polytef (Teflon)", JAMA, 251:24: 3277-3281 (1984). After 10 1/2 months, local and distant migration, including to the lungs and brains of test animals, was observed. Migration included particles having a greatest dimension of 80 microns. TEFLON
granulomas, signifying chronic foreign-body reaction, were found at all injection sites and some sites of distant migration.
Proper particle size selection is important. Studies in~ic~te that a particle size for Teflon tPTFE) in the range of between ~ and 100 microns is unacceptable for injectable material. Particles in this size range show local and distant migration, produce chronic inflammatory response in tissue, and has been associated with clinical complications. Particles that are too large are difficult to deposit e.g. will not go down a needle small enough to have clini r~ 1 application.
Thus, there remains a need for a treatment that ~ provides a lasting remedy with minimized side effects.
The primary focus of this invention has been directed toward the development of biocompatible, nonmigratory particles that are effectively delivered to the desired tissue site in a lubricative, biocompatible fluid or gel carrier. The preferred carrier shall not cause any deleterious effects at or near the site of particle delivery and will be removed from the site by normal biological or biochemical processes such as excretion or metabolic breakdown.
Summary of the Invention In accordance with the present invention there is provided an injectable, biocompatible composition comprised of a plurality of discrete, physiologically compatible, carbon or carbon-coated particles of a predetermined size range and a lubricative fluid or gel in which the particles are carried. The carrier is preferably a biologically compatible solution or suspension. The particles range in size from 100 microns to l,000 microns in transverse, cross-sectional dimension.
The composition is designed to be delivered into the body through a small-bore needle, cannula, or catheter to a tissue site for the purpose of augmenting the tissue site and surrounding area, thereby correcting a defect, filling a void or strengthening the support structures of the tissue.
The invention is comprised of two components. The first is a plurality of carbon or carbon-coated particles ranging in size as microbeads or microparticles from a minimum of 100 microns to a maximum of 1,000 microns. The carbon-coated particles can be created by sub~ecting an appropriate, particulate substrate to a coating process in which carbon is deposited as a thin coating or film, thereby creating a particle that has a highly biocompatible surface. The substrate material must be capable of withstanding the high temperature conditions of the coating process. Zirconium oxide and aluminum oxide have been found to be especially suitable as such a substrate.
3~ Carbon itself, such as non-pyrolytic carbon, may also be utilized as the particulate substrate. As an alternative to a substrate coated particle, low temperature isotropic (LTI), pyrolytic carbon alone can form a solid pyrolytic carbon bead.
The second component acts as the lubricative carrier for the carbon or carbon-coated particles and in the preferred embodiment is comprised of a suspension, solution, or other biologically compatible fluid or a gel.
One example of a biologically compatible carrier is methyl cellulose or other unbranched polysaccharide, either singly or in combination with one or more solutions well known in the art. Other lubricative carriers can include ~-glucan, hyaluronic acid and derivatives thereof, polyvinyl pyrrolidone or a hydrogel derivative thereof, dextrans or hydrogel derivatives thereof, glycerol, polyethylene glycol, succinaylated collagen, liquid collagen, and other polysaccharides or biocompati~le polymers, either singly or in combination with one or more of the above-referenced solutions. The preferred carrier must be capable of being formulated into a viscous fluid or into a self-supporting gel. For purposes of this invention, the carrier shall be of sufficient viscosity to suspend the particles for sufficient duration to inject the composition.
Brief Description of the Drawing The figure is a cross-sectional view of coated particles in accordance with the invention.
Detailed DescriPtion of the Preferred Embodiments The invention consists of an injectable composition that is a combination of a plurality of small, smooth-surfaced particles that are carried in a lubricative fluid or gel that is preferably comprised of a biologically compatible, lubricous solution, suspension, other fluid or gel.
In a first embodiment, the particles comprise microbeads or microparticles of a hard, material serving as a substrate and having a thin coating or film of biocompatible, isotropic carbon deposited on their surfaces. The substrate material is preferably radiopa~ue.
Different types of carbon coating processes may be W O98/01088 PCTfUS97110473 --utilized, with the particulate substrate being a substance selected for compatibility with the coating process. As shown in the figure which is a depiction from actual photomicrographs of particles produced in accordance with the present invention, the substrate particles are completely encased by the thin coating. This results in a smooth coated particle with no substrate exposure on the surface of the particle or in contact with tissue when injected.
Low temperature isotropic (LTI) pyrolytic carbon is a preferred carbon coating. Pyrolytic derives from the term pyrolysis, which is a thermal decomposition of hydrocarbons to produce a carbon material. Pyrolytic carbon is produced in a process in which hydrocarbons and alloying gases are decomposed in a fluidized or floating bed. Inert gas flow is used to float the bed and the substrate particles. The hydrocarbon pyrolysis results in high carbon, low hydrogen content spheres, which deposit as solids upon the substrate in the fluidized bed. As they deposit at temperatures of 1200~-1500~C, the spheres may coalesce, deform or grow due to atom movement, resulting in a high density coating. A
hard, metallic or ceramic substance capable of withs~An~ing the high temperature conditions of the coating process is the preferred substrate material.
Aluminum oxide is a preferred substrate material.
Zirconium oxide has also been found to be especially suitable as such a substrate. However, metallic substrates, including but not limited to medical grade stainless steel, titanium and titanium alloys and all oxide derivatives of each, are also quite acceptable as the substrate material. Using metal particles as substrates has the drawback of high cost. Due to increasing cost pressures, less expensive materials are desirable.
Applicants have also found that carbon itself maybe utilized as a satisfactory substrate material which is of low cost for the instant invention. The carbon substrate can be non-pyrolytic carbon. Thus, the beads in one W O 98/01088 PCT~S97110473 preferred embodiment may be comprised entirely of car~on.
In another preferred embodiment, a total pyrolytic carbon particle may comprise the bead.
Ultra-low-temperature isotropic carbon may be applied as a coating in vacuum vapor deposition processes. Carbon can be deposited effectively utilizing ion beams generated from the disassociation of CO2, reactive disassociation in vacuum of a hydrocarbon as a result of a glow discharge, sublimation of a solid graphite source or cathode sputtering of a graphite source, as examples of such processes. Gold has been found to be suitable as a substrate material ideal for vacuum vapor deposited carbon, however, other substrates, including but not limited to nickel, silver, stainless steel, or titanium are also quite accepta~le as the substrate material.
Vitreous or glass carbons may also serve as the coating material. These are also isotropic, monolithic carbons, which are formed by pyrolysis of carbonaceous preforms, during which gaseous pyrolysis products diffuse through the shape and are liberated.
The atomic structure of either pyrolitic LTI carbon or vitreous carbon is similar to graphite, the common form of carbon, but the alignment between hexagonal planes of atoms is not as well ordered. Pyrolitic carbon is characterized by a more chaotic atomic structure with warped hexagonal planes, missing atoms and generally a more turbostatic Appe~rance. This results in better bonding between layer planes.
The coating process is applied to small substrate particles to produce final, rounded particles that have a smooth carbon-coated surface in the form of a thin, black film. The resulting smooth surface on the particles ~nhAnces their passage through an injection needle, c~nn~l~A
or catheter and into body tissue. The high strength, resistance to breakdown or corrosion, and durability of the carbon coating insures the effective, long term functioning of the particles in tissue augmentation at the injection W 098/01088 PCTrUS97/10473 site. The established biocompatibility of pyrolytic carbon renders it particularly suitable for the anticipated body tissue applications.
After the carbon coating has been applied, the particles are subjected to a cleaning and sieving process to remove contaminants and to separate out particles of a size less than or greater than the desired size range. The particles may range in size from 100 microns to 1,000 microns in average, transverse cross-sectional dimension, and a preferred size range is between 200 and 500 microns.
A most preferred size range is between 251 and 300 microns.
The most preferred range avoids particle migration from the injection site yet allows injection through a small bore instrument. The substrate particles are initially milled, extruded or otherwise formed to the desired particle size, in a substantially rounded shape prior to being subjected to the coating process. The particles are randomly shaped and rounded, ranging from oblong to generally spherical.
The sieving process is such that the minimum particle dimension will pass through a U.S. No. 18 Screen Mesh (1000 micron grid size opening) but will not pass through a U.S.
No. 140 Screen Mesh (106 micron grid size). That minimum dimension will be the transverse, cross-sectional dimension on oblong or elongated particles, with that dimension coinciding with the particle diameter on generally spherical particles.
The carrier is preferably an aqueous suspension or solution, other fluid or gel of polymeric chains of B-D-glucose, commonly referred to as ~-glucan. The glucose units are linke~ to each other at the 1-3, 1-4, or 1-6 positions and form polymeric chains ranging to several thousand daltons in weight.
~-Glucan is a naturally occurring constituent of cell walls in essentially all living systems including plants, yeast, bacteria, and mamr-l;An systems. Its effects and modulating actions on living systems have been studied extensively (see Abel, G., and Czop, J.~ Stimulation of W O 98/01088 PCTrUS97/10473 Human Monocyte B-Glucan Receptors by Glucan Particles Induces Production of TNF-~ and lL-B", Int. J.
Immunopharmacol., 14(8):1363-1373, 1992 and references included therein). ~-glucan, when ~mi n; stered in experimental studies, elicits and augments host defense mechanisms including the steps required to promote healing by first intent, thereby stimulating the reparative processes in the host system. ~-glucan is rapidly removed from tissue sites through macrophagic phagocytosis or by enzymatic destruction by serous enzymes. The rapid destruction or L~ al of ~-glucan, as well as its available viscosity and lubricous nature, makes it an optimum carrier for the particles.
Aqueous solutions, suspensions, fluids, or gels of ~-glucan can be produced that have favorable physical characteristics as a carrier for solid carbon or carbon-coated particles. The viscosity can vary from a thin liquid to a firm, self-supporting gel. Irrespective of viscosity, the ~-glucan has excellent lubricity, thereby creating a particle-carrier composition which is easily ~i n; stered by delivery to a predetermined body site through a small bore needle, cannula, or catheter. A
preferred ~-glucan composition is ~-D glucan contAi n; ng 4-0-linked-~-D-glycopyranosyl units and 3-0-linked-~
glycopyranosyl units. The carrier will be of sufficient viscosity to assure that the carbon-coated particles remain suspended therein, for sufficient duration to complete the injection procedure.
Another preferred example of an appropriate carrier is methyl cellulose or other linear unbranched polysaccharide.
Further examples of appropriate carriers include hyaluronic acid, polyvinyl pyrrolidone or a hydrogel derivative thereof, dextran or a hydro~el derivative thereof, glycerol, polyethylene glycol, succinylated collagen, liquid collagen, oil based emulsions such as corn oil or o safflower, or other polysaccharides or biocompatible W O 98/01088 PCT~US97/10473 organic polymers either singly or in combination with one or more of the above-referenced solutions.
In use, the above-described composition will be in~ected in a fluid state, e.g., as a slurry, fluid suspension or emulsion, or as a gel through a syringe needle or cAnnlllA into a body tissue site. When deposited into a soft tissue site, the carrier will disperse or be destroyed as set forth above. The particles are of an optimum size which will prevent their being carried away by capillary blood flow. They will thus remain at the site and will serve to fill voids, provide additional support, or correct other soft-tissue defects.
The composition of the present invention may be utilized in urological applications. The composition may be injected into the tissues of the urinary tract, wherein the injection sites may be, for example, the sub-mucosal tissue plane of the bl~ r neck and/or urethra, the muscle fiber and adjoining tissues of the urethra and the tissues of the blA~er neck. These injection procedures are well described in the urologic literature, as demonstrated in Politano, V.A., "Periurethral Polytetrafluoroethylene Injection For Urinary Incontine~ae", J. Urol., 127: 439-442 (1982), and Appell, R.A., "Collagen Injection Therapy For Urinary Incontinence", Urol. Clin. N. Amer., 21: 177-182 (1994). The resulting bulking or augmentation of the urethral and hlA~er neck tissue will reduce the size o~
the bl~lA~r outlet and thus assist in controlling the patient's incontinence.
The present composition is also useful in fecal incontinence applications. U.S. Patent No. 5,480,644 to Freed discloses the use of collagen formulations and methods of repairing structurally defective or inA~Pquately functioning muscles of the anal sphincter. The compositions may be injected into the tissue of the anal canal, wherein the selected site may be, for example, the internal or external anal sphincter tissue. The resulting bulking or augmentation of the tissue will restrict the PCTrUS97/10473 size of the sphincter or anal passage and thus assist in overcoming fecal incontinence. Applicants also believe the present composition can be utilized in gastric reflux applications. The composition may be injected into the tissue of the upper gastrointestinal tract, wherein the selected site may be, for example, the cardiac orifice of the stomach which opens into the esophagus. The resulting bulking or augmentation of the tissue will restrict the - size of the passage and thus assist in overcoming gastric fluids refluxing into the esophagus.
Experimental Results In an experimental study, twelve dogs were implanted with a composition comprised of:
pyrolytic isotropic LTI carbon-coated zirconium oxide particles in a size range from 260 to 500 microns of a total mass of 400 mg suspe~e~ in 1 ml of: ~-glucan formulated as a 2.8% weight by weight aqueous suspension, as the carrier. The dosage was titrated to the individual animal but did not exceed 3 ml per An;m~l. The method of implantation was by injection into the periurethral tissues using a needle and syringe. A group of control ~n;m~l S
were injected with saline.
Each dog was closely observed over the balance of its time in the study, monitoring morbidity, mortality, body weight, food consumption and signs of overt toxicity.
Radiographs were taken postoperatively and prior to necropsy. Hematological, biochemical and urinalysis tests were conducted on all animals pre-test and at three month intervals for one year. Animals were euthanized for necropsy at three, six and twelve months and a thorough postmortem e~mi n~tion conducted. Protocol specified tissues were processed histologically and microscopic examination was conducted.
At each interval, the tissues showed only minor changes at the injection site. There were no signs of overt toxicity. No significant differences were noted in W O98/01088 PCTrUS97/10473 the body weights or weekly food consumption for the treated vs. control animals.
At the twelve month interval, the radiologic location of the carbon-coated beads was similar to that observed in the three and six month intervals. Technique problems at the time of injection had permitted particles to travel beyond the periurethral area in the immediate post-operative phase.
A second series of animal (dog) implants was done using the technique that most closely approximates the intended route of ~mi n ifftration in humans, periurethral injection via an endoscope. In addition to the above disclosed composition, a group of dogs were injected with the ~-glucan carrier gel alone. Dogs were euthanized at seven and twenty-eight days. The above biochPmlcAl and histological examinations were performed in this second series of test animals. There were no remarkable findings.
In summary, both series of animal implants, the dogs ~-~A~ine~ at three, six and twelve months and those examined at seven and twenty-eight days, show a healing process that is a normal foreign body reaction. The surrounding tissue quickly passes from an acute to sub-acute inflammatory phase and by three months, mature collagen has formed around the implanted carbon coated beads which remains stable through the first twelve months. No overt signs of toxicity were observed at any time. No evidence of migration of the implant material was noted.
These studies were conducted in accordance with good laboratory practices. They confirmed the handling characteristics of the test material as favorable; the material was easily injected with minimal to moderate resistance.
Numerous characteristics and advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly W O 98/01088 PCT~US97/10473 in matters of shape, size, and arrangement of parts without exceeding the scope of the invention. The inventions's scope is, of course, defined in the language in which the appended claims are expressed.
Background of the Invention This invention relates to an injectable composition of physiologically compatible and appropriately sized particles carried in a lubricative, biologically compatible fluid or gel. The composition is formulated to be delivered into the body to a tissue site through a small-bore instrument to strengthen, bulk-up and otherwise augment the tissue site and surrounding area.
The percutaneous injection of substances into tissues to augment, support, or reconfigure anatomic structure has been the subject of significant research and product development and is well known in the art. See, for example, U.S. Patent Nos. 4,803,075 and 5,204,382 to Wallace et al., and U.S. Patent No. 5,258,028 to Ersek et al. Procedures have been described in the medical literature for correction of dermatological, otolaryngological problems and for treatment of urological di60rders, e.g., Smith et al., "Evaluation of Polydimethylsiloxane as an Alternative in the Endoscopic Treatment of Vesicoureteral Reflux", J. Urol., 152: 1221-1224, 1994, and Walker et al., "Injectable Bioglass as a P o t e n t i a l S u b s t i t ut e f o r I n j e c t a b l e Polytetrafluoroethylene", J. Urol., 148:645-7 (1992) and the references cited therein.
Urinary incontinence and vesicourethral reflux are urological disorders that have responded to treatments with augumentive materials. Incontinence occurs when the resistance to urine flow has decreased to the point where the resistance can no longer resist the intra-abdominal pressure. Nearly all procedures developed to restore continence are based on restoring the lost resistance to urine outflow. U.S. Patent Nos. 5,007,940; 5,158,573; and 5,116,387 to Berg disclose biocompatible compositions comprising discrete, polymeric and silicone rubber bodies injectable into urethral tissue for the purpose of treatment of urinary incontinence by tissue bulking.
Further, U.S. Patent No. 5,451,406 to Lawin, the inventor of -the present composition, discloses biocompatible W O98101088 PCT~US97/10473 compositions comprising carbon coated substrate particles injectable into a tissue, such as the tissues of and that overlay the urethra and b~ r nec~, for the purpose of treatment of urinary incontinence by tissue bulking.
The most serious adverse effects that may occur from therapies of this type relate to the migration of the solid materials from the original site of placement into repository sites in various body organs and the chronic inflammatory response of tissue to particles that are too small. These adverse effects are well documented in the urologic literature, specifically in Malizia, A.A., et al., "Migration and Granulomatous Reaction After Periurethral Injection of Polytef (Teflon)", JAMA 251:3277-3281 ~1984) and Claes, H., Stroobants, D. et al., "Pulmonary Migration Following Periurethral Polytetrafluoroethylene In~ection For Urinary Incontinence", J. Urol., 142:821-822 (1989).
An important factor in assuring the absence of migration is the A~mi ni stration of properly sized particles. If the particle is too small, it can be engulfed by the body's white cells (phagocytes) and carried to distant organs or be carried away in the microvasculature and travel until it reaches a site of greater constriction. Target organs for deposition include the lungs, liver, spleen, brain, kidney, and lymph nodes.
The use of small diameter particulate spheres, in the range of 1-20 microns, and small elongate fibrils having a diameter in the range 1-20 microns, formed of materials such a~ cross linked collagen or synthetic polymers suspen~A in an aqueous medium having biocompatible lubricant has been disclosed in Wallace et al., U.S. Patent No. 4,803,075. While these materials showed positive, short term augmentation results, this result was short lived as the material had a te~ncy to migrate and/or be absorbed by the host tissue.
Teflon paste was used early to treat stress urinary incontinence. Politano, V.A., Small, M.P., Harper, J.M., Lynne, C.M., "Periurethral Teflon In~ection for Urinary W O 98/01088 PCT~US97/10473 Incontinence", J.Urol., 111:180-183 (1974). The Teflon paste consisted of polytetrafluoroethylene particles in a size range of 1 to 100 microns. More than ninety percent of the particles were in the range of 1 to 40 microns.
Malizia, A.A. Reiman, H.M., Myers, R.P., et al., "Migration and Granulomatous Reaction After Periurethral Injection of Polytef (Teflon)", JAMA, 251:24:3277-3281 (1984). This product demonstrated foreign body granuloma formation at the injection site and local migration. Boedts, D., Roels, H., Kluyskens, P., "Laryngeal Tissue Responses to Teflon", Arch Otolaryngol, 86:562-567 (1967).
In a 1980's study, TEFLON particles were injected periurethrally into monkeys and dogs, approximating the technique used to treat humans. Malizia, A.A. Reiman, H.M., Myers, R.P., et al., "Migration and Granulomatous Reaction After Periurethral Injection of Polytef (Teflon)", JAMA, 251:24: 3277-3281 (1984). After 10 1/2 months, local and distant migration, including to the lungs and brains of test animals, was observed. Migration included particles having a greatest dimension of 80 microns. TEFLON
granulomas, signifying chronic foreign-body reaction, were found at all injection sites and some sites of distant migration.
Proper particle size selection is important. Studies in~ic~te that a particle size for Teflon tPTFE) in the range of between ~ and 100 microns is unacceptable for injectable material. Particles in this size range show local and distant migration, produce chronic inflammatory response in tissue, and has been associated with clinical complications. Particles that are too large are difficult to deposit e.g. will not go down a needle small enough to have clini r~ 1 application.
Thus, there remains a need for a treatment that ~ provides a lasting remedy with minimized side effects.
The primary focus of this invention has been directed toward the development of biocompatible, nonmigratory particles that are effectively delivered to the desired tissue site in a lubricative, biocompatible fluid or gel carrier. The preferred carrier shall not cause any deleterious effects at or near the site of particle delivery and will be removed from the site by normal biological or biochemical processes such as excretion or metabolic breakdown.
Summary of the Invention In accordance with the present invention there is provided an injectable, biocompatible composition comprised of a plurality of discrete, physiologically compatible, carbon or carbon-coated particles of a predetermined size range and a lubricative fluid or gel in which the particles are carried. The carrier is preferably a biologically compatible solution or suspension. The particles range in size from 100 microns to l,000 microns in transverse, cross-sectional dimension.
The composition is designed to be delivered into the body through a small-bore needle, cannula, or catheter to a tissue site for the purpose of augmenting the tissue site and surrounding area, thereby correcting a defect, filling a void or strengthening the support structures of the tissue.
The invention is comprised of two components. The first is a plurality of carbon or carbon-coated particles ranging in size as microbeads or microparticles from a minimum of 100 microns to a maximum of 1,000 microns. The carbon-coated particles can be created by sub~ecting an appropriate, particulate substrate to a coating process in which carbon is deposited as a thin coating or film, thereby creating a particle that has a highly biocompatible surface. The substrate material must be capable of withstanding the high temperature conditions of the coating process. Zirconium oxide and aluminum oxide have been found to be especially suitable as such a substrate.
3~ Carbon itself, such as non-pyrolytic carbon, may also be utilized as the particulate substrate. As an alternative to a substrate coated particle, low temperature isotropic (LTI), pyrolytic carbon alone can form a solid pyrolytic carbon bead.
The second component acts as the lubricative carrier for the carbon or carbon-coated particles and in the preferred embodiment is comprised of a suspension, solution, or other biologically compatible fluid or a gel.
One example of a biologically compatible carrier is methyl cellulose or other unbranched polysaccharide, either singly or in combination with one or more solutions well known in the art. Other lubricative carriers can include ~-glucan, hyaluronic acid and derivatives thereof, polyvinyl pyrrolidone or a hydrogel derivative thereof, dextrans or hydrogel derivatives thereof, glycerol, polyethylene glycol, succinaylated collagen, liquid collagen, and other polysaccharides or biocompati~le polymers, either singly or in combination with one or more of the above-referenced solutions. The preferred carrier must be capable of being formulated into a viscous fluid or into a self-supporting gel. For purposes of this invention, the carrier shall be of sufficient viscosity to suspend the particles for sufficient duration to inject the composition.
Brief Description of the Drawing The figure is a cross-sectional view of coated particles in accordance with the invention.
Detailed DescriPtion of the Preferred Embodiments The invention consists of an injectable composition that is a combination of a plurality of small, smooth-surfaced particles that are carried in a lubricative fluid or gel that is preferably comprised of a biologically compatible, lubricous solution, suspension, other fluid or gel.
In a first embodiment, the particles comprise microbeads or microparticles of a hard, material serving as a substrate and having a thin coating or film of biocompatible, isotropic carbon deposited on their surfaces. The substrate material is preferably radiopa~ue.
Different types of carbon coating processes may be W O98/01088 PCTfUS97110473 --utilized, with the particulate substrate being a substance selected for compatibility with the coating process. As shown in the figure which is a depiction from actual photomicrographs of particles produced in accordance with the present invention, the substrate particles are completely encased by the thin coating. This results in a smooth coated particle with no substrate exposure on the surface of the particle or in contact with tissue when injected.
Low temperature isotropic (LTI) pyrolytic carbon is a preferred carbon coating. Pyrolytic derives from the term pyrolysis, which is a thermal decomposition of hydrocarbons to produce a carbon material. Pyrolytic carbon is produced in a process in which hydrocarbons and alloying gases are decomposed in a fluidized or floating bed. Inert gas flow is used to float the bed and the substrate particles. The hydrocarbon pyrolysis results in high carbon, low hydrogen content spheres, which deposit as solids upon the substrate in the fluidized bed. As they deposit at temperatures of 1200~-1500~C, the spheres may coalesce, deform or grow due to atom movement, resulting in a high density coating. A
hard, metallic or ceramic substance capable of withs~An~ing the high temperature conditions of the coating process is the preferred substrate material.
Aluminum oxide is a preferred substrate material.
Zirconium oxide has also been found to be especially suitable as such a substrate. However, metallic substrates, including but not limited to medical grade stainless steel, titanium and titanium alloys and all oxide derivatives of each, are also quite acceptable as the substrate material. Using metal particles as substrates has the drawback of high cost. Due to increasing cost pressures, less expensive materials are desirable.
Applicants have also found that carbon itself maybe utilized as a satisfactory substrate material which is of low cost for the instant invention. The carbon substrate can be non-pyrolytic carbon. Thus, the beads in one W O 98/01088 PCT~S97110473 preferred embodiment may be comprised entirely of car~on.
In another preferred embodiment, a total pyrolytic carbon particle may comprise the bead.
Ultra-low-temperature isotropic carbon may be applied as a coating in vacuum vapor deposition processes. Carbon can be deposited effectively utilizing ion beams generated from the disassociation of CO2, reactive disassociation in vacuum of a hydrocarbon as a result of a glow discharge, sublimation of a solid graphite source or cathode sputtering of a graphite source, as examples of such processes. Gold has been found to be suitable as a substrate material ideal for vacuum vapor deposited carbon, however, other substrates, including but not limited to nickel, silver, stainless steel, or titanium are also quite accepta~le as the substrate material.
Vitreous or glass carbons may also serve as the coating material. These are also isotropic, monolithic carbons, which are formed by pyrolysis of carbonaceous preforms, during which gaseous pyrolysis products diffuse through the shape and are liberated.
The atomic structure of either pyrolitic LTI carbon or vitreous carbon is similar to graphite, the common form of carbon, but the alignment between hexagonal planes of atoms is not as well ordered. Pyrolitic carbon is characterized by a more chaotic atomic structure with warped hexagonal planes, missing atoms and generally a more turbostatic Appe~rance. This results in better bonding between layer planes.
The coating process is applied to small substrate particles to produce final, rounded particles that have a smooth carbon-coated surface in the form of a thin, black film. The resulting smooth surface on the particles ~nhAnces their passage through an injection needle, c~nn~l~A
or catheter and into body tissue. The high strength, resistance to breakdown or corrosion, and durability of the carbon coating insures the effective, long term functioning of the particles in tissue augmentation at the injection W 098/01088 PCTrUS97/10473 site. The established biocompatibility of pyrolytic carbon renders it particularly suitable for the anticipated body tissue applications.
After the carbon coating has been applied, the particles are subjected to a cleaning and sieving process to remove contaminants and to separate out particles of a size less than or greater than the desired size range. The particles may range in size from 100 microns to 1,000 microns in average, transverse cross-sectional dimension, and a preferred size range is between 200 and 500 microns.
A most preferred size range is between 251 and 300 microns.
The most preferred range avoids particle migration from the injection site yet allows injection through a small bore instrument. The substrate particles are initially milled, extruded or otherwise formed to the desired particle size, in a substantially rounded shape prior to being subjected to the coating process. The particles are randomly shaped and rounded, ranging from oblong to generally spherical.
The sieving process is such that the minimum particle dimension will pass through a U.S. No. 18 Screen Mesh (1000 micron grid size opening) but will not pass through a U.S.
No. 140 Screen Mesh (106 micron grid size). That minimum dimension will be the transverse, cross-sectional dimension on oblong or elongated particles, with that dimension coinciding with the particle diameter on generally spherical particles.
The carrier is preferably an aqueous suspension or solution, other fluid or gel of polymeric chains of B-D-glucose, commonly referred to as ~-glucan. The glucose units are linke~ to each other at the 1-3, 1-4, or 1-6 positions and form polymeric chains ranging to several thousand daltons in weight.
~-Glucan is a naturally occurring constituent of cell walls in essentially all living systems including plants, yeast, bacteria, and mamr-l;An systems. Its effects and modulating actions on living systems have been studied extensively (see Abel, G., and Czop, J.~ Stimulation of W O 98/01088 PCTrUS97/10473 Human Monocyte B-Glucan Receptors by Glucan Particles Induces Production of TNF-~ and lL-B", Int. J.
Immunopharmacol., 14(8):1363-1373, 1992 and references included therein). ~-glucan, when ~mi n; stered in experimental studies, elicits and augments host defense mechanisms including the steps required to promote healing by first intent, thereby stimulating the reparative processes in the host system. ~-glucan is rapidly removed from tissue sites through macrophagic phagocytosis or by enzymatic destruction by serous enzymes. The rapid destruction or L~ al of ~-glucan, as well as its available viscosity and lubricous nature, makes it an optimum carrier for the particles.
Aqueous solutions, suspensions, fluids, or gels of ~-glucan can be produced that have favorable physical characteristics as a carrier for solid carbon or carbon-coated particles. The viscosity can vary from a thin liquid to a firm, self-supporting gel. Irrespective of viscosity, the ~-glucan has excellent lubricity, thereby creating a particle-carrier composition which is easily ~i n; stered by delivery to a predetermined body site through a small bore needle, cannula, or catheter. A
preferred ~-glucan composition is ~-D glucan contAi n; ng 4-0-linked-~-D-glycopyranosyl units and 3-0-linked-~
glycopyranosyl units. The carrier will be of sufficient viscosity to assure that the carbon-coated particles remain suspended therein, for sufficient duration to complete the injection procedure.
Another preferred example of an appropriate carrier is methyl cellulose or other linear unbranched polysaccharide.
Further examples of appropriate carriers include hyaluronic acid, polyvinyl pyrrolidone or a hydrogel derivative thereof, dextran or a hydro~el derivative thereof, glycerol, polyethylene glycol, succinylated collagen, liquid collagen, oil based emulsions such as corn oil or o safflower, or other polysaccharides or biocompatible W O 98/01088 PCT~US97/10473 organic polymers either singly or in combination with one or more of the above-referenced solutions.
In use, the above-described composition will be in~ected in a fluid state, e.g., as a slurry, fluid suspension or emulsion, or as a gel through a syringe needle or cAnnlllA into a body tissue site. When deposited into a soft tissue site, the carrier will disperse or be destroyed as set forth above. The particles are of an optimum size which will prevent their being carried away by capillary blood flow. They will thus remain at the site and will serve to fill voids, provide additional support, or correct other soft-tissue defects.
The composition of the present invention may be utilized in urological applications. The composition may be injected into the tissues of the urinary tract, wherein the injection sites may be, for example, the sub-mucosal tissue plane of the bl~ r neck and/or urethra, the muscle fiber and adjoining tissues of the urethra and the tissues of the blA~er neck. These injection procedures are well described in the urologic literature, as demonstrated in Politano, V.A., "Periurethral Polytetrafluoroethylene Injection For Urinary Incontine~ae", J. Urol., 127: 439-442 (1982), and Appell, R.A., "Collagen Injection Therapy For Urinary Incontinence", Urol. Clin. N. Amer., 21: 177-182 (1994). The resulting bulking or augmentation of the urethral and hlA~er neck tissue will reduce the size o~
the bl~lA~r outlet and thus assist in controlling the patient's incontinence.
The present composition is also useful in fecal incontinence applications. U.S. Patent No. 5,480,644 to Freed discloses the use of collagen formulations and methods of repairing structurally defective or inA~Pquately functioning muscles of the anal sphincter. The compositions may be injected into the tissue of the anal canal, wherein the selected site may be, for example, the internal or external anal sphincter tissue. The resulting bulking or augmentation of the tissue will restrict the PCTrUS97/10473 size of the sphincter or anal passage and thus assist in overcoming fecal incontinence. Applicants also believe the present composition can be utilized in gastric reflux applications. The composition may be injected into the tissue of the upper gastrointestinal tract, wherein the selected site may be, for example, the cardiac orifice of the stomach which opens into the esophagus. The resulting bulking or augmentation of the tissue will restrict the - size of the passage and thus assist in overcoming gastric fluids refluxing into the esophagus.
Experimental Results In an experimental study, twelve dogs were implanted with a composition comprised of:
pyrolytic isotropic LTI carbon-coated zirconium oxide particles in a size range from 260 to 500 microns of a total mass of 400 mg suspe~e~ in 1 ml of: ~-glucan formulated as a 2.8% weight by weight aqueous suspension, as the carrier. The dosage was titrated to the individual animal but did not exceed 3 ml per An;m~l. The method of implantation was by injection into the periurethral tissues using a needle and syringe. A group of control ~n;m~l S
were injected with saline.
Each dog was closely observed over the balance of its time in the study, monitoring morbidity, mortality, body weight, food consumption and signs of overt toxicity.
Radiographs were taken postoperatively and prior to necropsy. Hematological, biochemical and urinalysis tests were conducted on all animals pre-test and at three month intervals for one year. Animals were euthanized for necropsy at three, six and twelve months and a thorough postmortem e~mi n~tion conducted. Protocol specified tissues were processed histologically and microscopic examination was conducted.
At each interval, the tissues showed only minor changes at the injection site. There were no signs of overt toxicity. No significant differences were noted in W O98/01088 PCTrUS97/10473 the body weights or weekly food consumption for the treated vs. control animals.
At the twelve month interval, the radiologic location of the carbon-coated beads was similar to that observed in the three and six month intervals. Technique problems at the time of injection had permitted particles to travel beyond the periurethral area in the immediate post-operative phase.
A second series of animal (dog) implants was done using the technique that most closely approximates the intended route of ~mi n ifftration in humans, periurethral injection via an endoscope. In addition to the above disclosed composition, a group of dogs were injected with the ~-glucan carrier gel alone. Dogs were euthanized at seven and twenty-eight days. The above biochPmlcAl and histological examinations were performed in this second series of test animals. There were no remarkable findings.
In summary, both series of animal implants, the dogs ~-~A~ine~ at three, six and twelve months and those examined at seven and twenty-eight days, show a healing process that is a normal foreign body reaction. The surrounding tissue quickly passes from an acute to sub-acute inflammatory phase and by three months, mature collagen has formed around the implanted carbon coated beads which remains stable through the first twelve months. No overt signs of toxicity were observed at any time. No evidence of migration of the implant material was noted.
These studies were conducted in accordance with good laboratory practices. They confirmed the handling characteristics of the test material as favorable; the material was easily injected with minimal to moderate resistance.
Numerous characteristics and advantages of the invention covered by this document have been set forth in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly W O 98/01088 PCT~US97/10473 in matters of shape, size, and arrangement of parts without exceeding the scope of the invention. The inventions's scope is, of course, defined in the language in which the appended claims are expressed.
Claims (19)
1. An injectable, biocompatible composition for tissue augmentation comprising:
a plurality of discrete particles in a carrier, wherein the particles are substrate particles with a carbon coating, said substrate particles selected from the group consisting of aluminum oxide and carbon, and have an average transverse cross sectional dimension of between 100 and 1,000 microns wherein the carrier is a biocompatible medium having sufficient fluidity to carry and deliver the particles, and has lubricative qualities.
a plurality of discrete particles in a carrier, wherein the particles are substrate particles with a carbon coating, said substrate particles selected from the group consisting of aluminum oxide and carbon, and have an average transverse cross sectional dimension of between 100 and 1,000 microns wherein the carrier is a biocompatible medium having sufficient fluidity to carry and deliver the particles, and has lubricative qualities.
2. The composition of claim 1 wherein said carbon coating is isotropic carbon.
3. The composition of claim 1 wherein said carbon coating is pyrolytic, isotropic carbon.
4. The composition of claim 1 wherein said carbon coating is a smooth surface film.
5. The composition of claim 1 wherein said substrate particles are of rounded shape and said dimension is between 200 microns and 500 microns.
6. The composition of claim 1 wherein said substrate particles are of rounded shape and said dimension is between 251 microns and 300 microns.
7. The composition of claim 1 wherein said average transverse cross section dimension is between 251 microns and 300 microns.
8. An injectable, biocompatible composition for tissue augmentation comprising:
a plurality of discrete particles of pyrolytic carbon in a carrier, and having an average transverse cross sectional dimension of between 100 and 1,000 microns and the carrier is a biocompatible medium having sufficient fluidity to carry and deliver the particles, and has lubricative qualities.
a plurality of discrete particles of pyrolytic carbon in a carrier, and having an average transverse cross sectional dimension of between 100 and 1,000 microns and the carrier is a biocompatible medium having sufficient fluidity to carry and deliver the particles, and has lubricative qualities.
9. An injectable, biocompatible composition for tissue augmentation comprising:
a plurality of discrete particles in a carrier, wherein the particles are substrate particles with a carbon coating and have an average transverse cross sectional dimension of between 100 and 1,000 microns and the carrier is a biocompatible medium having sufficient fluidity to carry and deliver the particles, wherein said carrier is a solution, suspension, or gel of polysaccharides.
a plurality of discrete particles in a carrier, wherein the particles are substrate particles with a carbon coating and have an average transverse cross sectional dimension of between 100 and 1,000 microns and the carrier is a biocompatible medium having sufficient fluidity to carry and deliver the particles, wherein said carrier is a solution, suspension, or gel of polysaccharides.
10. The composition of claim 9 wherein said polysaccharides are linear, unbranched polysaccharides.
11. The composition of claim 9 wherein said carrier is a solution, suspension, or gel of methyl cellulose.
12. The method of claim 9 wherein said carrier is .beta.-glucan.
13. A method for augmenting tissue in a human patient comprising injecting into a tissue site in the patient a composition comprising a plurality of discrete, carbon or carbon-coated particles having an average, transverse, cross-sectional dimension of between 100 and 1,000 microns in a biocompatible carrier having sufficient fluidity to carry and deliver the particles and has lubricative qualities, wherein the tissue site is the coronary orifice to the stomach.
14. The method of claim 13 wherein said carrier is .beta.-glucan.
15. A method for augmenting tissue in a human patient comprising injecting into a tissue site in the patient a composition comprising a plurality of discrete, carbon or carbon-coated particles having an average, transverse, cross-sectional dimension of between 100 and 1,000 microns in a biocompatible carrier having sufficient fluidity to carry and deliver the particles and has lubricative qualities, wherein the tissue site is the anal canal.
16. The method of claim 15 wherein the tissue site is the internal sphincter muscle of the anal canal.
17. The method of claim 15 wherein the tissue site is the external sphincter muscle of the anal canal.
18. The method of claim 15 wherein said substrate particles are of rounded shape and said dimension is between 200 microns and 500 microns.
19. The method of claim 15 wherein said substrate particles are of rounded shape and said dimension is between 251 microns and 300 microns.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/676,592 US5792478A (en) | 1996-07-08 | 1996-07-08 | Tissue injectable composition and method of use |
US08/676,592 | 1996-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2260048A1 true CA2260048A1 (en) | 1998-01-15 |
Family
ID=24715138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002260048A Abandoned CA2260048A1 (en) | 1996-07-08 | 1997-06-17 | Improved tissue injectable composition and method of use |
Country Status (8)
Country | Link |
---|---|
US (1) | US5792478A (en) |
EP (1) | EP0918498B1 (en) |
JP (1) | JP2000515134A (en) |
AT (1) | ATE287681T1 (en) |
CA (1) | CA2260048A1 (en) |
DE (1) | DE69732358D1 (en) |
ES (1) | ES2236815T3 (en) |
WO (1) | WO1998001088A1 (en) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7060287B1 (en) * | 1992-02-11 | 2006-06-13 | Bioform Inc. | Tissue augmentation material and method |
US6537574B1 (en) | 1992-02-11 | 2003-03-25 | Bioform, Inc. | Soft tissue augmentation material |
US7968110B2 (en) * | 1992-02-11 | 2011-06-28 | Merz Aesthetics, Inc. | Tissue augmentation material and method |
US6214331B1 (en) * | 1995-06-06 | 2001-04-10 | C. R. Bard, Inc. | Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained |
US6309420B1 (en) * | 1997-10-14 | 2001-10-30 | Parallax Medical, Inc. | Enhanced visibility materials for implantation in hard tissue |
US6660301B1 (en) * | 1998-03-06 | 2003-12-09 | Biosphere Medical, Inc. | Injectable microspheres for dermal augmentation and tissue bulking |
CN1714783A (en) * | 1998-03-06 | 2006-01-04 | 生物领域医疗公司 | Implantable particles for tissue bulking and the treatment |
AU3203599A (en) | 1998-04-01 | 1999-10-18 | Parallax Medical, Inc. | Pressure applicator for hard tissue implant placement |
US6591838B2 (en) | 1998-07-06 | 2003-07-15 | Scimed Life Systems, Inc. | Implant system and method for bulking tissue |
US6251064B1 (en) | 1998-12-11 | 2001-06-26 | Enteric Medical Technologies, Inc. | Method for creating valve-like mechanism in natural body passageway |
US6238335B1 (en) * | 1998-12-11 | 2001-05-29 | Enteric Medical Technologies, Inc. | Method for treating gastroesophageal reflux disease and apparatus for use therewith |
US9320588B2 (en) * | 1998-12-11 | 2016-04-26 | Boston Scientific Scimed, Inc. | Method for treating fecal incontinence |
US7132582B2 (en) * | 2003-05-30 | 2006-11-07 | Council Of Scientific And Industrial Research | Catalytic process for the preparation of isolongifolene |
US6595910B2 (en) * | 1998-12-11 | 2003-07-22 | Scimed Life Systems, Inc. | Method for treating fecal incontinence |
AU6168699A (en) | 1999-03-24 | 2000-10-09 | Parallax Medical, Inc. | Non-compliant system for delivery of implant material |
US6565550B1 (en) | 1999-05-10 | 2003-05-20 | Carbon Medical Technologies, Inc. | Luer fitting injector |
US6821285B2 (en) | 1999-06-22 | 2004-11-23 | Ndo Surgical, Inc. | Tissue reconfiguration |
US6663639B1 (en) | 1999-06-22 | 2003-12-16 | Ndo Surgical, Inc. | Methods and devices for tissue reconfiguration |
US8287554B2 (en) | 1999-06-22 | 2012-10-16 | Ethicon Endo-Surgery, Inc. | Method and devices for tissue reconfiguration |
US7846180B2 (en) | 1999-06-22 | 2010-12-07 | Ethicon Endo-Surgery, Inc. | Tissue fixation devices and methods of fixing tissue |
US6835200B2 (en) | 1999-06-22 | 2004-12-28 | Ndo Surgical. Inc. | Method and devices for tissue reconfiguration |
US6494888B1 (en) * | 1999-06-22 | 2002-12-17 | Ndo Surgical, Inc. | Tissue reconfiguration |
US6358197B1 (en) | 1999-08-13 | 2002-03-19 | Enteric Medical Technologies, Inc. | Apparatus for forming implants in gastrointestinal tract and kit for use therewith |
US6277392B1 (en) * | 1999-09-16 | 2001-08-21 | Carbon Medical Technologies, Inc. | Tissue injectable composition |
US6431174B1 (en) * | 2000-08-10 | 2002-08-13 | Pi Medical, Inc. | Method and apparatus to treat conditions of the naso-pharyngeal area |
US6502574B2 (en) | 1999-09-17 | 2003-01-07 | Pi Medical, Inc. | Lateral stiffening snoring treatment |
US6783515B1 (en) | 1999-09-30 | 2004-08-31 | Arthrocare Corporation | High pressure delivery system |
EP1114618A3 (en) | 2000-01-04 | 2001-08-22 | Ethicon Endo-Surgery, Inc. | Surgical instrument for applying beads to tissue |
WO2001070289A2 (en) | 2000-03-20 | 2001-09-27 | Biosphere Medical, Inc. | Injectable and swellable microspheres for tissue bulking |
US7338657B2 (en) * | 2001-03-15 | 2008-03-04 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
US6436424B1 (en) * | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
US6540789B1 (en) | 2000-06-15 | 2003-04-01 | Scimed Life Systems, Inc. | Method for treating morbid obesity |
US6355275B1 (en) | 2000-06-23 | 2002-03-12 | Carbon Medical Technologies, Inc. | Embolization using carbon coated microparticles |
US7737109B2 (en) | 2000-08-11 | 2010-06-15 | Temple University Of The Commonwealth System Of Higher Education | Obesity controlling method |
EP1307218B1 (en) | 2000-08-11 | 2011-01-05 | Temple University - Of The Commonwealth System of Higher Education | Treatment of obesity |
US6394965B1 (en) | 2000-08-15 | 2002-05-28 | Carbon Medical Technologies, Inc. | Tissue marking using biocompatible microparticles |
US6296607B1 (en) * | 2000-10-20 | 2001-10-02 | Praxis, Llc. | In situ bulking device |
US9080146B2 (en) | 2001-01-11 | 2015-07-14 | Celonova Biosciences, Inc. | Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface |
US20070191964A1 (en) * | 2001-04-04 | 2007-08-16 | Arthrocare Corporation | Enhanced visibility materials for implantation in hard tissue |
US7017582B2 (en) * | 2002-02-04 | 2006-03-28 | Restore Medical Inc. | Stiffening pharyngeal wall treatment |
US7146981B2 (en) | 2002-02-04 | 2006-12-12 | Restore Medical, Inc. | Pharyngeal wall treatment |
US20030161824A1 (en) * | 2002-02-27 | 2003-08-28 | Rackley Raymond R. | Bulking agent needle apparatus and method of using the needle apparatus |
JP2005524659A (en) * | 2002-02-27 | 2005-08-18 | カーボン・メディカル・テクノロジーズ・インコーポレーテッド | Lower esophageal tissue regulator |
US20030171451A1 (en) * | 2002-03-11 | 2003-09-11 | White Daniel A. | Bony tissue fillers and restoratives containing biocompatible particle |
US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
US20040105890A1 (en) * | 2002-05-28 | 2004-06-03 | Carbon Medical Technologies, Inc. | Biocompatible injectable materials |
US20040028676A1 (en) * | 2002-08-06 | 2004-02-12 | Klein Dean A. | Swallowing system tissue modifier |
AU2003240000A1 (en) | 2002-06-12 | 2003-12-31 | Boston Scientific Limited | Bulking agents |
US7842377B2 (en) | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
US20040194266A1 (en) * | 2002-08-19 | 2004-10-07 | Carter Linda A. | Burn, sunburn, and cellulite treatment system |
US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
US7992566B2 (en) | 2002-12-30 | 2011-08-09 | Quiescence Medical, Inc. | Apparatus and methods for treating sleep apnea |
US7647931B2 (en) | 2002-12-30 | 2010-01-19 | Quiescence Medical, Inc. | Stent for maintaining patency of a body region |
US7381222B2 (en) * | 2002-12-30 | 2008-06-03 | Quiescence Medical, Inc. | Stent for maintaining patency of a body region |
US20050033157A1 (en) * | 2003-07-25 | 2005-02-10 | Klein Dean A. | Multi-modality marking material and method |
WO2005012364A2 (en) * | 2003-07-30 | 2005-02-10 | Anteis S.A. | Complex matrix for biomedical use |
US7976823B2 (en) | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
US8092527B2 (en) * | 2003-09-03 | 2012-01-10 | Brennan William A | System and method for breast augmentation |
US7169180B2 (en) * | 2003-09-03 | 2007-01-30 | Brennan William A | System and method for breast augmentation |
US7645229B2 (en) | 2003-09-26 | 2010-01-12 | Armstrong David N | Instrument and method for endoscopic visualization and treatment of anorectal fistula |
US7381180B2 (en) * | 2003-10-31 | 2008-06-03 | Medtronic, Inc. | Implantable devices and methods for treating fecal incontinence |
US7585271B2 (en) * | 2003-11-01 | 2009-09-08 | Thd Spa | Implantable devices and methods for treating urinary incontinence |
US8124120B2 (en) * | 2003-12-22 | 2012-02-28 | Anika Therapeutics, Inc. | Crosslinked hyaluronic acid compositions for tissue augmentation |
US20060074447A2 (en) | 2004-01-21 | 2006-04-06 | Cook Incorporated | Implantable graft to close a fistula |
US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
DE602005014860D1 (en) * | 2004-04-23 | 2009-07-23 | Jacobus Adriaan Albertus Kotze | CERAMIC BULKING MEDIUM |
US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
US9114162B2 (en) | 2004-10-25 | 2015-08-25 | Celonova Biosciences, Inc. | Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same |
US20210299056A9 (en) | 2004-10-25 | 2021-09-30 | Varian Medical Systems, Inc. | Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods |
US9107850B2 (en) | 2004-10-25 | 2015-08-18 | Celonova Biosciences, Inc. | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
US8425550B2 (en) | 2004-12-01 | 2013-04-23 | Boston Scientific Scimed, Inc. | Embolic coils |
US7727555B2 (en) | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
EP1903947B1 (en) | 2005-06-21 | 2015-12-30 | Cook Medical Technologies LLC | Implantable graft to close a fistula |
US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
US20070102010A1 (en) * | 2005-10-07 | 2007-05-10 | Lemperle Stefan M | Naso-pharyngeal tissue engineering |
US8007509B2 (en) | 2005-10-12 | 2011-08-30 | Boston Scientific Scimed, Inc. | Coil assemblies, components and methods |
US8152839B2 (en) | 2005-12-19 | 2012-04-10 | Boston Scientific Scimed, Inc. | Embolic coils |
US8101197B2 (en) | 2005-12-19 | 2012-01-24 | Stryker Corporation | Forming coils |
US7947368B2 (en) | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
US20070184087A1 (en) | 2006-02-06 | 2007-08-09 | Bioform Medical, Inc. | Polysaccharide compositions for use in tissue augmentation |
WO2007130953A2 (en) | 2006-05-01 | 2007-11-15 | Duodyn Technology, Llc | Apparatus and method for managing incontinence |
JP5406025B2 (en) * | 2006-07-06 | 2014-02-05 | クワイエセンス メディカル インコーポレイテッド | Apparatus and system for treatment of sleep apnea |
US8414927B2 (en) | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Cross-linked polymer particles |
US20080107744A1 (en) * | 2006-11-06 | 2008-05-08 | Jack Fa-De Chu | Injectable hollow tissue filler |
US8852216B2 (en) | 2007-03-23 | 2014-10-07 | Ethicon Endo-Surgery, Inc. | Tissue approximation methods |
US8038721B2 (en) * | 2007-12-17 | 2011-10-18 | Anna Love | Soft tissue filler |
US20100016808A1 (en) * | 2008-07-17 | 2010-01-21 | Bioform Medical, Inc. | Thin-Walled Delivery System |
US20100160715A1 (en) * | 2008-12-23 | 2010-06-24 | Yiming Deng | Method of minimal invasive tunneling |
US9265649B2 (en) | 2010-12-13 | 2016-02-23 | Quiescence Medical, Inc. | Apparatus and methods for treating sleep apnea |
US8551525B2 (en) | 2010-12-23 | 2013-10-08 | Biostructures, Llc | Bone graft materials and methods |
WO2012174234A2 (en) | 2011-06-14 | 2012-12-20 | Cook Medical Technologies Llc | Fistula closure devices and methods |
US20210214749A1 (en) | 2018-05-16 | 2021-07-15 | Voyager Therapeutics, Inc. | Directed evolution |
MX2020013875A (en) | 2018-06-27 | 2021-08-11 | Pivot Bio Inc | Agricultural compositions comprising remodeled nitrogen fixing microbes. |
AU2019250128A1 (en) | 2018-10-15 | 2020-04-30 | Avent Inc. | Compositions, systems, kits, and methods for neural ablation |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3638649A (en) * | 1969-07-07 | 1972-02-01 | Univ Minnesota | Implantable prosthetic pass-through device |
US3657744A (en) * | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
US3783868A (en) * | 1971-05-06 | 1974-01-08 | Gulf Oil Corp | Percutaneous implant |
US3977896A (en) * | 1972-03-09 | 1976-08-31 | General Atomic Company | Process for depositing pyrolytic carbon coatings |
US4197846A (en) * | 1974-10-09 | 1980-04-15 | Louis Bucalo | Method for structure for situating in a living body agents for treating the body |
US4129470A (en) * | 1974-10-17 | 1978-12-12 | Homsy Charles A | Method of preparing a porous implantable material from polytetrafluoroethylene and carbon fibers |
US4239492A (en) * | 1979-06-14 | 1980-12-16 | Beisang Arthur A | Method of preparing vascular grafts of human and other umbilical cord origins for tissue ingrowth |
US4240794A (en) * | 1979-06-25 | 1980-12-23 | Beisang Arthur A | Method of preforming vascular grafts of human and other animal origin |
US4424208A (en) * | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
US4527293A (en) * | 1983-05-18 | 1985-07-09 | University Of Miami | Hydrogel surface of urological prosthesis |
US4469676A (en) * | 1983-06-21 | 1984-09-04 | Michel Hecmati | Method for eliminating wrinkles occurring in the human skin |
MX163953B (en) * | 1984-03-27 | 1992-07-03 | Univ New Jersey Med | PROCEDURE FOR PREPARING A BIODEGRADABLE COLLAGEN MATRIX |
US4563350A (en) * | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
US5001169A (en) * | 1984-10-24 | 1991-03-19 | Collagen Corporation | Inductive collagen-based bone repair preparations |
CA1260391A (en) * | 1985-03-28 | 1989-09-26 | Karl A. Piez | Xenogeneic collagen/mineral preparations in bone repair |
US4992226A (en) * | 1985-03-28 | 1991-02-12 | Collagen Corporation | Method of making molds with xenogeneic collagen/mineral preparations for bone repair |
US4776890A (en) * | 1985-12-18 | 1988-10-11 | Collagen Corporation | Preparation of collagen hydroxyapatite matrix for bone repair |
US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
US4773393A (en) * | 1986-07-03 | 1988-09-27 | C. R. Bard, Inc. | Hypodermically implantable genitourinary prosthesis |
US4865602A (en) * | 1986-11-06 | 1989-09-12 | Collagen Corporation | Gamma irradiation of collagen/mineral mixtures |
US4902511A (en) * | 1987-07-28 | 1990-02-20 | Kronman Joseph H | Fibrous and cartilaginous tissue replacement |
US4863732A (en) * | 1987-12-16 | 1989-09-05 | Collagen Corporation | Injectable composition for inductive bone repair |
US5011494A (en) * | 1988-09-16 | 1991-04-30 | Clemson University | Soft tissue implant with micron-scale surface texture to optimize anchorage |
US5306500A (en) * | 1988-11-21 | 1994-04-26 | Collagen Corporation | Method of augmenting tissue with collagen-polymer conjugates |
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5258028A (en) * | 1988-12-12 | 1993-11-02 | Ersek Robert A | Textured micro implants |
US5158573A (en) * | 1989-06-09 | 1992-10-27 | American Medical Systems, Inc. | Injectable polymeric bodies |
US5116387A (en) * | 1989-06-09 | 1992-05-26 | American Medical Systems, Inc. | Preparation of injectable polymeric bodies |
US5007940A (en) * | 1989-06-09 | 1991-04-16 | American Medical Systems, Inc. | Injectable polymeric bodies |
US5256418A (en) * | 1990-04-06 | 1993-10-26 | Organogenesis, Inc. | Collagen constructs |
US5246698A (en) * | 1990-07-09 | 1993-09-21 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5480644A (en) * | 1992-02-28 | 1996-01-02 | Jsf Consultants Ltd. | Use of injectable biomaterials for the repair and augmentation of the anal sphincters |
US5204382A (en) * | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
JPH07504106A (en) * | 1992-02-28 | 1995-05-11 | コラーゲン コーポレイション | Injectable ceramic compositions and methods for their manufacture and use |
WO1993019702A1 (en) * | 1992-04-06 | 1993-10-14 | Uroplasty, Inc. | Treatment of reflux disorder by microparticles injection |
AU4381793A (en) * | 1992-05-20 | 1993-12-13 | Cytrx Corporation | Gel composition for implant prosthesis and method of use |
US5451406A (en) * | 1994-07-14 | 1995-09-19 | Advanced Uroscience, Inc. | Tissue injectable composition and method of use |
-
1996
- 1996-07-08 US US08/676,592 patent/US5792478A/en not_active Expired - Lifetime
-
1997
- 1997-06-17 EP EP97931215A patent/EP0918498B1/en not_active Expired - Lifetime
- 1997-06-17 WO PCT/US1997/010473 patent/WO1998001088A1/en active IP Right Grant
- 1997-06-17 CA CA002260048A patent/CA2260048A1/en not_active Abandoned
- 1997-06-17 AT AT97931215T patent/ATE287681T1/en not_active IP Right Cessation
- 1997-06-17 ES ES97931215T patent/ES2236815T3/en not_active Expired - Lifetime
- 1997-06-17 DE DE69732358T patent/DE69732358D1/en not_active Expired - Lifetime
- 1997-06-17 JP JP10505207A patent/JP2000515134A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2000515134A (en) | 2000-11-14 |
ES2236815T3 (en) | 2005-07-16 |
EP0918498A1 (en) | 1999-06-02 |
EP0918498B1 (en) | 2005-01-26 |
EP0918498A4 (en) | 2001-04-11 |
ATE287681T1 (en) | 2005-02-15 |
WO1998001088A1 (en) | 1998-01-15 |
DE69732358D1 (en) | 2005-03-03 |
US5792478A (en) | 1998-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5792478A (en) | Tissue injectable composition and method of use | |
US6277392B1 (en) | Tissue injectable composition | |
US5451406A (en) | Tissue injectable composition and method of use | |
AU674308B2 (en) | Use of injectable biomaterials for the repair and augmentation of the anal sphincters | |
JP2995090B2 (en) | Compositions and methods for tissue augmentation | |
US20040028676A1 (en) | Swallowing system tissue modifier | |
US7491243B2 (en) | Method of modifying a lower esophagus | |
JP3004724B2 (en) | Treatment of reflux obstruction by microparticle injection | |
JPH07504106A (en) | Injectable ceramic compositions and methods for their manufacture and use | |
US8002845B2 (en) | Materials and methods for soft tissue augmentation | |
Tsai et al. | Injectable biomaterials for incontinence and vesico‐ureteral reflux: Current status and future promise | |
US20040105890A1 (en) | Biocompatible injectable materials | |
Mann-Gow et al. | Novel bioceramic urethral bulking agents elicit improved host tissue responses in a rat model | |
Mann-Gow et al. | Research Article Novel Bioceramic Urethral Bulking Agents Elicit Improved Host Tissue Responses in a Rat Model | |
JP2005524659A (en) | Lower esophageal tissue regulator | |
CN117462753A (en) | Surface modified implant for long-acting slow-release active protein and preparation method and application thereof | |
Russinko et al. | Endoscopic correction of reflux | |
JP2001247483A (en) | Infusion for preventing urine incontinence and vesicoureteral reflux |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |